Transcept shares soar on revived NDA hopes for Intermezzo

Shares of Transcept Pharmaceuticals ($TSPT) shot up more than 70% after the biotech laid out plans to resubmit its sleep drug Intermezzo to the FDA--after the agency green-lighted its plan to adjust dosing based on gender and fine-tune the timing instructions on the label.

Transcept was handed a rejection on Intermezzo a few months ago after regulators raised a red flag that the drug--a reformulated, sublingual version of Ambien (zolpidem tartrate)--could be unsafe for some patients who used it in the middle of the night. The agency felt that any residual levels of the drug could interfere with driving--a key safety hurdle for many new insomnia treatments.

The biotech's response was to agree to reduce the dosing level for women--from 3.5 mg to 1.75 mg--keep the same dose for men and add to the amount of time a person would need to wait before getting behind the wheel after taking a dose. And the FDA's approach, Transcept added, would allow the biotech to resubmit the app this month without additional trials and with the prospect of a two-month review.

That formula seemed just right for some of the company's backers, who started pushing up the stock price in after-hours trading.

- check out the Transcept release
- read the story from the Wall Street Journal

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.